A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jun 12, 2001
  • Application: Oct 16, 1996
    US US 73314296 A
  • Priority: Oct 16, 1996
    US US 73314296 A
  • Priority: Feb 29, 1996
    US US 60877696 A
  • Priority: Oct 26, 1995
    US US 707195 P

Download Citation

Sign in to the Lens